TGFβ is historically known to be pro-tumorigenic in nature and has resulted in the development of several small molecule inhibitors targeting this pathway for use in the clinic.28 TGFβ can suppress the host immune response to cancer in a myriad of ways, including, but not limited to, promotion of angiogenesis and epithelial to mesenchymal transition, impairment of CD8+ T cells and NK cells, reducing T cell infiltration to the tumor, and recruitment of M2 macrophages and MDSCs. Here, CD8A is linked to cancer.